There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School of Medicine, Durham, NC, USA) discusses the unmet needs in reducing the risk of CKD in people with T2D as well as the rationale for the combination of finerenone and empagliflozin in the prevention of CKD in patients with T2D.
The abstract entitled: ‘Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)‘Â was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What are the unmet needs in reducing the risk of chronic kidney disease (CKD) in people with type 2 diabetes (T2D)? (0:18)
- What is the rationale for the combination of finerenone and empagliflozin in the prevention of CKD in patients with T2D? (1:15)
Disclosures: Jennifer Green discloses grant/research support from Boehringer Ingelheim/Lilly, Merck and Roche.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
